Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis

Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko; Ishiguro, Naoki; Ryu, Junnosuke; Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Fujii, Koichi; Yoshinaga, Takunari; Freundlich, Bruce; Suzukawa, Michio

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis

Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko et al.

Rheumatology International, 2012, 32(6), 1511-1519

Permalink : https://hdl.handle.net/2115/49677

このアイテムのアクセス数:1,302件（2026-08-09 14:12 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
RI32-6_1511-1519	pdf	416 KB	1,292

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/49677
タイトル	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
著者	Koike, Takao ; Harigai, Masayoshi ; Inokuma, Shigeko ; Ishiguro, Naoki ; Ryu, Junnosuke ; Takeuchi, Tsutomu ; Tanaka, Yoshiya ; Yamanaka, Hisashi ; Fujii, Koichi ; Yoshinaga, Takunari ; Freundlich, Bruce ; Suzukawa, Michio
e-Rad_Researcher 80146795 著者名 Koike, Takao
著者名 Harigai, Masayoshi
著者名 Inokuma, Shigeko
著者名 Ishiguro, Naoki
著者名 Ryu, Junnosuke
著者名 Takeuchi, Tsutomu
著者名 Tanaka, Yoshiya
著者名 Yamanaka, Hisashi
著者名 Fujii, Koichi
著者名 Yoshinaga, Takunari
著者名 Freundlich, Bruce
著者名 Suzukawa, Michio
言語	英語
キーワード	Antirheumatic agents/adverse effects
	Antirheumatic agents/therapeutic use
	Arthritis, rheumatoid/drug therapy
	Product surveillance, Postmarketing/statistics & numerical data
	Receptors, tumor necrosis factor/therapeutic use
	Japan
発行日	2012-06
出版者	Springer Berlin / Heidelberg
収録物名	Rheumatology International
巻(号)	32(6)
ページ	1511-1519
抄録	The aim is to investigate the relationship of duration of rheumatoid arthritis (RA) with safety and effectiveness of etanercept (ETN) in Japan. Post-marketing surveillance data for 7,099 patients treated with ETN were analyzed. Baseline characteristics, treatment effectiveness, incidence of adverse events (AEs), and serious AEs (SAEs) in relation to duration of RA were studied. At baseline, patients with RA for longer duration were older, weighed less, had more comorbidities, allergies, and corticosteroid use, but smoked less and had less morning stiffness. By 2-5 years with RA, more than half of the patients had advanced to Steinbrocker radiographic stage III or IV. Methotrexate (MTX) was the most commonly used pre-treatment disease-modifying antirheumatic drug; however, concomitant MTX use and its dose were lower among patients with longer duration of RA. Remission rates (26.6%) were greatest among patients having RA for <2 years. Less AEs and SAEs were observed among patients with shorter duration of RA. These results suggest that RA treatment in Japan in the era pre-biologics may not have been adequate to control disease activity and prevent joint destruction. Patients with shorter duration of RA may have better physical status which allows the opportunity to treat more intensively putting a higher percentage of patients in remission and possibly decreasing exposure to SAEs.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	0172-8172
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1007/s00296-010-1784-8